Literature DB >> 27109513

The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent.

G Kong1, Y-I Chang1,2, X You1, E A Ranheim3, Y Zhou1, C E Burd4,5, J Zhang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27109513      PMCID： PMC5347394          DOI： 10.1038/leu.2016.89

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

Review 1.  RAS oncogenes: the first 30 years.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

2.  Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.

Authors:  G Kong; Y-I Chang; A Damnernsawad; X You; J Du; E A Ranheim; W Lee; M-J Ryu; Y Zhou; Y Xing; Q Chang; C E Burd; J Zhang
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

3.  Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Authors:  Christin E Burd; Wenjin Liu; Minh V Huynh; Meriam A Waqas; James E Gillahan; Kelly S Clark; Kailing Fu; Brit L Martin; William R Jeck; George P Souroullas; David B Darr; Daniel C Zedek; Michael J Miley; Bruce C Baguley; Sharon L Campbell; Norman E Sharpless
Journal:  Cancer Discov       Date:  2014-09-24       Impact factor: 39.397

Review 4.  Targeting oncogenic Ras signaling in hematologic malignancies.

Authors:  Ashley F Ward; Benjamin S Braun; Kevin M Shannon
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

5.  Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Authors:  Jinyong Wang; Yangang Liu; Zeyang Li; Zhongde Wang; Li Xuan Tan; Myung-Jeom Ryu; Benjamin Meline; Juan Du; Ken H Young; Erik Ranheim; Qiang Chang; Jing Zhang
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

Review 6.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

7.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Authors:  Guangyao Kong; Mark Wunderlich; David Yang; Erik A Ranheim; Ken H Young; Jinyong Wang; Yuan-I Chang; Juan Du; Yangang Liu; Sin Ruow Tey; Xinmin Zhang; Mark Juckett; Ryan Mattison; Alisa Damnernsawad; Jingfang Zhang; James C Mulloy; Jing Zhang
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

8.  Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

Authors:  Jinyong Wang; Guangyao Kong; Yangang Liu; Juan Du; Yuan-I Chang; Sin Ruow Tey; Xinmin Zhang; Erik A Ranheim; Marc K Saba-El-Leil; Sylvain Meloche; Alisa Damnernsawad; Jingfang Zhang; Jing Zhang
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113

9.  Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

Authors:  Jin Xu; Kevin M Haigis; Ari J Firestone; Megan E McNerney; Qing Li; Elizabeth Davis; Shann-Ching Chen; Joy Nakitandwe; James Downing; Tyler Jacks; Michelle M Le Beau; Kevin Shannon
Journal:  Cancer Discov       Date:  2013-06-03       Impact factor: 39.397

10.  Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.

Authors:  Jinyong Wang; Yangang Liu; Zeyang Li; Juan Du; Myung-Jeom Ryu; Philip R Taylor; Mark D Fleming; Ken H Young; Henry Pitot; Jing Zhang
Journal:  Blood       Date:  2010-10-04       Impact factor: 22.113
View more
  13 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.

Authors:  Özgün Le Roux; Nicole L K Pershing; Erin Kaltenbrun; Nicole J Newman; Jeffrey I Everitt; Elisa Baldelli; Mariaelena Pierobon; Emanuel F Petricoin; Christopher M Counter
Journal:  Elife       Date:  2022-09-07       Impact factor: 8.713

3.  Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.

Authors:  Brandon M Murphy; Elizabeth M Terrell; Venkat R Chirasani; Tirzah J Weiss; Rachel E Lew; Andrea M Holderbaum; Aastha Dhakal; Valentina Posada; Marie Fort; Michael S Bodnar; Leiah M Carey; Min Chen; Craig J Burd; Vincenzo Coppola; Deborah K Morrison; Sharon L Campbell; Christin E Burd
Journal:  Nat Commun       Date:  2022-06-07       Impact factor: 17.694

Review 4.  The mystery of oncogenic KRAS: Lessons from studying its wild-type counter part.

Authors:  Yuan-I Chang; Alisa Damnernsawad; Guangyao Kong; Xiaona You; Demin Wang; Jing Zhang
Journal:  Small GTPases       Date:  2016-07-22

5.  Unique dependence on Sos1 in Kras G12D -induced leukemogenesis.

Authors:  Xiaona You; Guangyao Kong; Erik A Ranheim; David Yang; Yun Zhou; Jing Zhang
Journal:  Blood       Date:  2018-10-30       Impact factor: 22.113

6.  Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.

Authors:  James M Cleary; Victoria Wang; Rebecca S Heist; E Scott Kopetz; Edith P Mitchell; James A Zwiebel; Kevin S Kapner; Helen X Chen; Shuli Li; Robert J Gray; Lisa M McShane; Larry V Rubinstein; David R Patton; Funda Meric-Bernstam; Melissa S Dillmon; P Mickey Williams; Stanley R Hamilton; Barbara A Conley; Andrew J Aguirre; Peter J O'Dwyer; Lyndsay N Harris; Carlos L Arteaga; Alice P Chen; Keith T Flaherty
Journal:  Clin Cancer Res       Date:  2021-02-26       Impact factor: 12.531

7.  Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.

Authors:  Xiaona You; Fabao Liu; Moritz Binder; Alexis Vedder; Terra Lasho; Zhi Wen; Xin Gao; Evan Flietner; Adhithi Rajagopalan; Yun Zhou; Christy Finke; Abhishek Mangaonkar; Ruiqi Liao; Guangyao Kong; Erik A Ranheim; Nathalie Droin; Anthony M Hunter; Sergey Nikolaev; Maria Balasis; Omar Abdel-Wahab; Ross L Levine; Britta Will; Kalyan Vara Ganesh Nadiminti; David Yang; Klaus Geissler; Eric Solary; Wei Xu; Eric Padron; Mrinal M Patnaik; Jing Zhang
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

8.  Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.

Authors:  Zhi Wen; Adhithi Rajagopalan; Evan D Flietner; Grant Yun; Marta Chesi; Quinlan Furumo; Robert T Burns; Athanasios Papadas; Erik A Ranheim; Adam C Pagenkopf; Zachary T Morrow; Remington Finn; Yun Zhou; Shuyi Li; Xiaona You; Jeffrey Jensen; Mei Yu; Alexander Cicala; James Menting; Constantine S Mitsiades; Natalie S Callander; P Leif Bergsagel; Demin Wang; Fotis Asimakopoulos; Jing Zhang
Journal:  Blood       Date:  2021-01-07       Impact factor: 25.476

9.  Identification of genes and pathways potentially related to PHF20 by gene expression profile analysis of glioblastoma U87 cell line.

Authors:  Tianlong Liu; Tiejun Zhang; Feng Zhou; Jitao Wang; Xiaohu Zhai; Nan Mu; Jongsun Park; Minna Liu; Wenxing Liu; Peijin Shang; Yi Ding; Aidong Wen; Yuwen Li
Journal:  Cancer Cell Int       Date:  2017-10-04       Impact factor: 5.722

10.  Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.

Authors:  Edward C Stites; Andrey S Shaw
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.